AU2016276269B2 - Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof - Google Patents

Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof Download PDF

Info

Publication number
AU2016276269B2
AU2016276269B2 AU2016276269A AU2016276269A AU2016276269B2 AU 2016276269 B2 AU2016276269 B2 AU 2016276269B2 AU 2016276269 A AU2016276269 A AU 2016276269A AU 2016276269 A AU2016276269 A AU 2016276269A AU 2016276269 B2 AU2016276269 B2 AU 2016276269B2
Authority
AU
Australia
Prior art keywords
polysaccharide
serotype
protein
composition
conjugated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016276269A
Other languages
English (en)
Other versions
AU2016276269A1 (en
Inventor
Rajeev Mhalasakant DHERE
Manish Maheshkumar GAUTAM
Prashant Shivaji JADHAV
Swapan Kumar Jana
Chetan Vilas JOSHI
Sunil MAHOR
Venkata Vamsi Krishna MALEPATI
Asha Dinesh MALLYA
Hitesh Kumar Malviya
Sambhaji Shankar PISAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serum Institute of India Pvt Ltd
Original Assignee
Serum Institute of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute of India Pvt Ltd filed Critical Serum Institute of India Pvt Ltd
Publication of AU2016276269A1 publication Critical patent/AU2016276269A1/en
Application granted granted Critical
Publication of AU2016276269B2 publication Critical patent/AU2016276269B2/en
Priority to AU2024202450A priority Critical patent/AU2024202450A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016276269A 2015-06-08 2016-06-03 Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof Active AU2016276269B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024202450A AU2024202450A1 (en) 2015-06-08 2024-04-15 Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2185MU2015 2015-06-08
IN2185/MUM/2015 2015-06-08
PCT/IB2016/053265 WO2016199003A1 (en) 2015-06-08 2016-06-03 Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024202450A Addition AU2024202450A1 (en) 2015-06-08 2024-04-15 Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof

Publications (2)

Publication Number Publication Date
AU2016276269A1 AU2016276269A1 (en) 2018-01-18
AU2016276269B2 true AU2016276269B2 (en) 2021-01-28

Family

ID=57503115

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016276269A Active AU2016276269B2 (en) 2015-06-08 2016-06-03 Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof
AU2024202450A Pending AU2024202450A1 (en) 2015-06-08 2024-04-15 Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024202450A Pending AU2024202450A1 (en) 2015-06-08 2024-04-15 Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof

Country Status (17)

Country Link
US (1) US10729780B2 (enExample)
EP (1) EP3302542A4 (enExample)
JP (2) JP7258463B2 (enExample)
KR (2) KR102690378B1 (enExample)
CN (1) CN107847571A (enExample)
AU (2) AU2016276269B2 (enExample)
CA (1) CA2988366C (enExample)
CO (1) CO2017012628A2 (enExample)
EA (1) EA201792470A1 (enExample)
IL (1) IL256118B (enExample)
MX (1) MX2017015985A (enExample)
MY (1) MY187461A (enExample)
PE (1) PE20180460A1 (enExample)
PH (1) PH12017502244A1 (enExample)
SA (1) SA517390495B1 (enExample)
WO (1) WO2016199003A1 (enExample)
ZA (1) ZA201708325B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102045663B1 (ko) 2015-05-04 2019-11-15 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
PE20180460A1 (es) * 2015-06-08 2018-03-06 Serum Inst Of India Private Ltd Metodos para mejorar la adsorcion de conjugados de polisacarido-proteina y una formulacion de vacuna multivalente obtenida con los mismos
CN106822884B (zh) * 2016-12-28 2021-04-30 北京民海生物科技有限公司 一种多价肺炎球菌荚膜多糖结合疫苗的制备方法
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
MX2019007910A (es) 2016-12-30 2019-12-05 Sutrovax Inc Conjugados de polipeptido-antigeno con aminoacidos no naturales.
US20200054740A1 (en) * 2017-02-24 2020-02-20 Merck Sharp & Dohme Corp. Pneumococcal conjugate vaccine formulations
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
US11491216B2 (en) * 2017-09-07 2022-11-08 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US11116828B2 (en) 2017-12-06 2021-09-14 Merck Sharp & Dohme Corp. Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CN108524926B (zh) * 2018-06-29 2021-06-29 康希诺生物股份公司 一种多价肺炎球菌结合疫苗的制剂组合及其应用
GB201818517D0 (en) * 2018-11-13 2018-12-26 Univ Liverpool John Moores Nanoparticles and uses thereof
BR112021011961A8 (pt) 2018-12-19 2023-02-07 Merck Sharp & Dohme Composições compreendendo conjugados de polissacarídeo-proteína de streptococcus pneumoniae e métodos de uso dos mesmos
CA3142692A1 (en) * 2019-06-05 2020-12-10 Merck Sharp & Dohme Corp. An immunogenic serotype 35b pneumococcal polysaccharide-protein conjugate and conjugation process for making the same
US12473379B2 (en) 2019-09-06 2025-11-18 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
CN113607939B (zh) * 2021-08-05 2024-10-22 艾美探索者生命科学研发有限公司 肺炎球菌多糖结合疫苗各型结合原液吸附率测定方法
CN115006522B (zh) * 2022-06-16 2025-08-22 北京智飞绿竹生物制药有限公司 一种双价痢疾结合物组合疫苗的制备方法
MX2024004116A (es) 2023-04-17 2024-11-08 Serum Institute Of India Pvt Ltd Metodos para mejorar la adsorcion de conjugados de polisacarido-proteina y formulacion de vacuna multivalente obtenida de los mismos

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209450A1 (en) * 2007-06-26 2010-08-19 Ralph Leon Biemans Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
US20130273098A1 (en) * 2010-12-10 2013-10-17 Jeffrey T. Blue Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
ES2411080T3 (es) * 2003-01-30 2013-07-04 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
CN102151331B (zh) 2003-08-06 2013-10-30 美国政府健康及人类服务部 多糖-蛋白轭合物疫苗
WO2006113528A2 (en) * 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics Inc. Expressing hepatitis b virus surface antigen for vaccine preparation
DK2384765T3 (en) * 2005-12-22 2017-01-09 Glaxosmithkline Biologicals Sa Vaccine against Streptococcus pneumoniae.
KR20080079697A (ko) * 2005-12-23 2008-09-01 글락소스미스클라인 바이오로지칼즈 에스.에이. 컨쥬게이트 백신
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
SI2809349T1 (sl) * 2012-01-30 2019-03-29 Serum Institute Of India Private Limited Imunogeni sestavek
KR102057217B1 (ko) * 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CA2881420C (en) * 2012-08-16 2016-11-15 Pfizer Inc. Glycoconjugation processes and compositions
CN103893751B (zh) * 2014-03-26 2016-04-20 天津康希诺生物技术有限公司 一种肺炎球菌多糖蛋白缀合疫苗及其制备方法
PE20180460A1 (es) * 2015-06-08 2018-03-06 Serum Inst Of India Private Ltd Metodos para mejorar la adsorcion de conjugados de polisacarido-proteina y una formulacion de vacuna multivalente obtenida con los mismos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209450A1 (en) * 2007-06-26 2010-08-19 Ralph Leon Biemans Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
US20130273098A1 (en) * 2010-12-10 2013-10-17 Jeffrey T. Blue Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions

Also Published As

Publication number Publication date
EP3302542A1 (en) 2018-04-11
KR20180030498A (ko) 2018-03-23
CA2988366A1 (en) 2016-12-15
KR102876828B1 (ko) 2025-10-27
CO2017012628A2 (es) 2018-03-28
MX2017015985A (es) 2018-08-15
IL256118A (en) 2018-02-28
CN107847571A (zh) 2018-03-27
EP3302542A4 (en) 2019-04-10
EA201792470A1 (ru) 2018-10-31
CA2988366C (en) 2021-12-07
US10729780B2 (en) 2020-08-04
JP2021185152A (ja) 2021-12-09
SA517390495B1 (ar) 2023-03-23
ZA201708325B (en) 2019-05-29
NZ738090A (en) 2023-09-29
KR102690378B1 (ko) 2024-08-01
PE20180460A1 (es) 2018-03-06
IL256118B (en) 2021-12-01
AU2024202450A1 (en) 2024-10-31
KR20240007690A (ko) 2024-01-16
JP7258463B2 (ja) 2023-04-17
AU2016276269A1 (en) 2018-01-18
BR112017026343A2 (pt) 2019-11-19
US20180161445A1 (en) 2018-06-14
JP2018516962A (ja) 2018-06-28
PH12017502244A1 (en) 2018-06-11
MY187461A (en) 2021-09-23
WO2016199003A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
AU2016276269B2 (en) Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof
CN104302315B (zh) 免疫原性组合物及其制备方法
JP7329087B2 (ja) ナイセリア・メニンギティディスのワクチン
JP2021522285A (ja) リオスフィアから肺炎連鎖球菌莢膜多糖類キャリアタンパク質コンジュゲートを生産する方法
CN103083652B (zh) 一种以异型双功能试剂为连接桥的脑膜炎多糖结合疫苗及其制备方法
US20220211859A1 (en) Conjugate production
OA19863A (en) Methods for improving the adsorption of polysaccharide-Protein conjugates and multivalent vaccine formulation obtained thereof.
TW201932140A (zh) 用於改善多糖—蛋白質共軛物及其獲得的多價疫苗配製劑的吸附的方法
TW201818960A (zh) 使用低分子化ＰＲＰ之Ｈｉｂ接合型疫苗之製造方法
EA040838B1 (ru) Устойчивая поливалентная вакцинная композиция и способ ее получения
BR112017026343B1 (pt) Métodos para aperfeiçoar a adsorção de conjugados de proteínapolissacarídeo e formulação de vacina multivalente assim obtida
EP4450082A1 (en) Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof
KR20200005458A (ko) 다가 폐렴구균 다당체-단백질 접합체를 포함하는 면역원성 조성물, 및 이를 포함하는 약학 조성물
CN117866036A (zh) 一种基于硫醇点击化学制备多糖结合疫苗的方法及其产品

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)